We are at a transformational time in biomedical research. Disruptive technologies have made human disease models a reality. Patient-derived material lies at the heart of this effort, which we at Ksilink access through our clinical programs. The models we are creating recapitulate the actual disease mechanisms in patients. Drug development, has been vertically accelerated as a result. Costs are lessened and chances of success bolstered. During this paradigm shift access to patient material and modeling know how is becoming a competitive game changer. Ksilink is designed to be at the forefront of this new development.